Table 1 Characteristics of the patients
Edoxaban 15 mg (n = 23) | Edoxaban 30 mg (n = 209) | p value | |
|---|---|---|---|
Sex | |||
Male | 6 (26.1%) | 51 (24.4%) | 0.80 |
Female | 17 (73.9%) | 158 (75.6%) | |
Age (years), median (IQR) | 81 (77.5–86.5) | 71 (65–78) | < 0.01 |
Body weight (kg), median (IQR) | 55 (51.7–65.3) | 60.4 (51.0–69.1) | 0.31 |
Body mass index, median (IQR) | 23.8 (21.8–29.8) | 25.8 (22.1–28.2) | 0.73 |
Creatinine clearance (mL/min), median (IQR) | 44.5 (38.1–47.0) | 101.4 (79.4–125.1) | < 0.01 |
Surgical intervention | |||
TKA | 10 (43.5%) | 65 (31.1%) | 0.56 |
THA | 9 (39.1%) | 94 (45.0%) | |
HFS | 3 (13.0%) | 25 (12.0%) | |
UKA | 1 (4.3%) | 25 (12.0%) | |
Medical history | |||
Intracranial hemorrhage | 1 (4.3%) | 6 (2.9%) | 0.52 |
Gastrointestinal bleeding | 1 (4.3%) | 4 (1.9%) | 0.41 |
Venous thromboembolism | 0 | 3 (1.4%) | 1.00 |
Malignant tumor | 1 (4.3%) | 18 (8.6%) | 0.70 |
Concomitant medication | |||
P-glycoprotein inhibitor | 1 (4.3%) | 2 (1.0%) | 0.27 |
Antiplatelet agent | 3 (13.0%) | 11 (5.3%) | 0.15 |
Statin | 9 (39.1%) | 59 (28.2%) | 0.33 |
Estrogen | 0 | 0 | 1.00 |
SERM | 0 | 6 (2.9%) | 1.00 |
Adrenal corticosteroid | 2 (8.7%) | 8 (3.8%) | 0.26 |
Antipsychotic drug | 2 (8.7%) | 5 (2.4%) | 0.15 |
Antidepressant | 3 (13.0%) | 8 (3.8%) | 0.08 |
Tranexamic acid | 0 | 3 (1.4%) | 1.00 |